Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer’s disease

Bibliography

• SELKOE DJ: Aging brain, aging mind. Sci. Am. (1992) 267:134–142.
   PubMed Web of Science ®Google Scholar
• GOTTFIRES CG: Alzheimer's disease and senile demen-tia: biochemical characteristics and aspects of treat-ment. Psychopharmacology (1985) 86:245–252.
   PubMed Web of Science ®Google Scholar
• BOWEN DM, SMITH CB, WHITE P, DAVISON AN: Neuro-transmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 99:459–496.
   PubMed Web of Science ®Google Scholar
• DAVIES P, MALONEY AJ: Selective loss of central cholin-ergic neurons in Alzheimer's disease. Lancet (1976) 2:1403.
   PubMed Web of Science ®Google Scholar
• PERRY EK, PERRY RH, BLESSED G, THOMLINSON BE: Necropsy evidence of central cholinergic deficits in senile dementia [Letter]. Lancet (1977) i:189.
   Google Scholar
• SUMMERS WK, MAJOVSKI LV, MARSH GM, TACHIKI K, KLING A: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. New Engl. J. Med. (1986) 315:1241–1245.
   PubMed Web of Science ®Google Scholar
• MCEVOY GK (Ed.): Tacrine. AHFS Drug Information (1997):906–909.
   Google Scholar
• GREGOR VE, EMMERLING MR, LEE C, MOORE CJ: The synthesis and in vitro acetylcholinesterase and butyryl-cholinesterase inhibitory activity of tacrine (Cognexim) derivatives. Bioorg. Med. Chem. Lett. (1992) 2:861–864.
   Web of Science ®Google Scholar
• NOCHI S, ASAKAWA N, SATO T: Kinetic study on the inhibition of acetylcholinesterase by 1-benzy1-445,6-di-methoxy-1-indanon)-2-yllmethylpiperidine hydro-chloride (E2020). Biol. Pharm. Bull. (1995) 18:1145–1147.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, IIMURA Y, YAMANISHI Y, YAMATSU K: Synthesis and structure-activity relationships of acetyl-cholinesterase inhibitors: 1-benzy1-4-[(5,6-dimethoxy-1-oxoindan-2-yfimethyl]piperidine hydrochloride and related compounds. J Med. Chem. (1995) 38:4821–4829.
   PubMed Web of Science ®Google Scholar
• GALLI A, MORI F, BENINI L, CACCIARELLI N: Acetylcholi-nesterase protection and the anti-diisopropylfluoro-phosphate efficacy of E2020. Eric. J. Pharmacol (1994) 270:189–193.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, YAMANISHI Y, YAMATSU K: E2020 - the pharmacology of a piperidine cholinesterase inhibitor.Cholinergic Basis for Alzheimer Therapy Becker R, Giacobini E (Eds.), Birkhauser, Boston (1991):314–320. A brief but thorough review of the pharmacology of donepezil.
   Google Scholar
• YAMANISHI Y, OGURA H, KOSASA T, ARAKI S, SAWA Y, YAMATSU K: Inhibitory action of E2020, a novel acetyl-cholinesterase inhibitor, on cholinesterase: compari-son with other inhibitors. Adv. Behav. Biol. (1990) 2(38B):409–413.
   Google Scholar
• ARAKI S, YAMANISHI Y, KOSASA T, OGURA H, YAMATSU K: E2020, a novel centrally acting acetylcholinesterase inhibitor. 1. Inhibitory action on cholinesterase. Jpn. Pharrnacol (1989) 49:155P.
   Google Scholar
• YAMANISHI Y, ARAKI S, KOSASA T, OGURA H, YAMATSU K: Neurochemical studies of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. (1988) 14:59.
   Google Scholar
• UN JH, HU GY, TANG XC: Comparison between hu-perzine A, tacrine, and E2020 on cholinergic transmis-sion at mouse neuromuscular junction in vitro. Acta Pharmacologica Sinica (1997) 18:6–10.
   Web of Science ®Google Scholar
• SNAPE MF, ANDERSON SMP, MISRA A et al.: A comparison of the cholinesterase inhibitors tacrine and E-2020. Br. J. Pharmacol (1996) 117 (Suppl.):163P.
   Google Scholar
• GIACOBINI E, ZHU XD, WILLIAMS E, SHERMAN KA: The •effect of selective reversible acetylcholinesterase in-hibitor E2020 on extracellular acetylcholine and bio-genic amine levels in rat cortex. Neuropharmacology (1996) 35:205-211. An evaluation of the neurochemical effects of donepezil after in vivo administration.
   Google Scholar
• KAWASHIMA K, SATO A, YOSHIZAWA M et al. Effects of centrally acting cholinesterase inhibitors tetrahy-droaminoacridine and E2020 on the basal concentra-tion of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Arch. Phar-macol (1994) 350:523–528.
   PubMed Web of Science ®Google Scholar
• KOSASA T, OGURA H, UCHIKOSHI K et al.: E2020, a novel centrally acting acetylcholinesterase inhibitor (4): com-parison of the effects of single and repeated administra-tion on cerebral cholinergic system in rats. Jpn. Pharmacol (1990) 52:359P.
   Google Scholar
• YAMANISHI Y, KOSASA T, OGURA H, ARAKI S, YAMATSU K: E2020, a novel centrally acting acetylcholinesterase inhibitor (2): neurochemical studies of acetylcholine metabolism. Jpn. J. Pharmacol (1989) 49:301P.
   PubMedGoogle Scholar
• YAMANISHI Y, OGURA H, KOSASA T et al.: Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats. Eur. J. Pharmacol (1990) 183:1935.
   Web of Science ®Google Scholar
• KIRKBY DL, JONES DNC, BARNES JC, HIGGINS GA: Effects of anticholinesterase drugs tacrine and E2020, the 5-11T3 antagonist ondansetron, and the 113 antagonist thioperamide in models of cognition and cholinergic function. Behav. Pharmacol (1996) 7:513-525. Results from behavioural studies with donepezil, tacrine, and other agents.
   Google Scholar
• WANIBUCHI F, NISHIDA T, YAMASHITA H et al.: Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur.J Pharmacol. (1994) 265:151–158.
   PubMed Web of Science ®Google Scholar
• DAWSON GR, IVERSEN SD: The effects of novel choli- nesterase inhibitors and selective muscarinic receptoragonists in tests of reference and working memory. Behav. Brain Res. (1993) 57:143-153. A comparison of several cholinomimetic agents in tests of learning and memory.
   Google Scholar
• DAWSON GR, HEYES CM, IVERSEN SD: Pharmacological •mechanisms and animal models of cognition. Behav. Pharmacol (1992) 3:285-297. A thorough review of animal models of cognition.
   Google Scholar
• DAWSON GR, BAYLEY P, CHANNELL S, IVERSEN SD: Acomparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory. Psychopharmacology (1994) 113:361–368.
   PubMed Web of Science ®Google Scholar
• BRAIDA D, PALADINI E, GRIFFINI P et al.: An invertedU-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eric. J. Pharmacol. (1996) 302:13–20.
   PubMed Web of Science ®Google Scholar
• OGURA H, KOSASA T, ARAKI S, YAMANISHI Y, YAMATSUK: Behavioral study of E-2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. (1988) 14:60.
   Google Scholar
• OGURA H, KOSASA T, ARAKI S, YAMANISHI Y, YAMATSUK: E2020, a novel centrally acting acetylcholinesterase inhibitor (3): behavioral study of cholinergic action in rats. Jpn. J. Pharmacol (1989) 49:155P.
   PubMedGoogle Scholar
• SUZUKI M, YAMAGUCHI T, OZAWA Y, OHYAMA M, YAMAMOTO M: Effects of (-)-S-2,8-dimethy1-3-methylene-1-oxa-8-azaspiro [4,5]decane L-tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug treated and senescence accelerated mice. J. Phar-macol Exp. Ther. (1995) 275:728–736.
   PubMed Web of Science ®Google Scholar
• SMITH RD, KISTLER MK, COHEN-WILLIAMS N, COFFIN VL:Cholinergic improvement of a naturally-occurring memory deficit in the young rat. Brain Res. (1996) 707:13–21.
   PubMed Web of Science ®Google Scholar
• MATSUI K, ODA Y, OHE H, TANAKA S, ASAKAWA N: Directdetermination of E2020 enantiomers in plasma by liquid chromatography-mass spectrometry and col-umn-switching techniques. J. Chromatography A (1995) 694:209–218.
   PubMed Web of Science ®Google Scholar
• MIHARA M, OHNISHI A, TOMONO Y et al: Pharmacoki- netics of E2020, a new compound for Alzheimer'sdisease, in healthy male volunteers. Int. J. Gun. Pharma-col. Ther. Toxicol (1993) 31:223-229. A study of the pharmacokinetics of donepezil after single and multiple doses.
   Google Scholar
• ROGERS SL, WALTERS EJ, FRIEDHOFF LT: The pharma-cokinetics (PK) and pharmacodynamics (PD) of E2020 ((R,S,) -1- benxy1-4- ( (5,6-dim ethoxy-1-indannon)- 2-y0 methylpiperidine hydrochloride), a novel inhibitor of acetylcholine sterase (AChE): implications for use in the treatment of Alzheimer's disease. Neurobiol Aging (1992) 13(Suppl.):S125–5126.
   Google Scholar
• OHNISHI A, MIHARA M, KAMAKURA H et al.: Comparison of the pharmacokinetics of E2020, a new compound forAlzheimer's disease, in healthy young and elderly sub-jects. J. Chn. Pharmacol. (1993) 33:1086-1091. A study of the pharmacokinetics of donepezil in elderly subjects.
   Google Scholar
• TISEO PJ, ROGERS SL, FRIEDHOFF LT: The pharrnacoki-netic profile of donepezil HC1 (E2020) in patients with impaired liver function. Clin. Pharmacol Ther. (1997) 61:184.
   Google Scholar
• ROGERS SL, TISEO PJ, FRIEDHOFF LT: Pharmacokineticsof donepezil HC1 (132020) are unchanged in patients with impaired renal function. Clin. Pharmacol Ther. (1997) 61:217.
   Google Scholar
• ROGERS SL, FRIEDHOFF LT: The pharmacokinetic (PK) and pharmacodynamic (PD) profile of donepezil HC1 (132020) following single and multiple oral doses. Gin. Pharmacol. Ther. (1997) 61:181.
   Google Scholar
• ANONYMOUS: Donepezil (Ariceptim) for Alzheimer's disease. Medical Letter on Drugs and Therapeutics (1997) 39\(Issue 1004:53–54.
   Google Scholar
• HOMMA A, HASEGAWA K: Recent clinical trials of choli-nomimetics for patients with Alzheimer's disease in Japan. Adv. Behav. Biol. (1995) 44:437–448.
   Google Scholar
• ROGERS SL, FRIEDHOFF LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: resultsof a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia (1996) 7:293-303. Results from a large scale Phase II trial with donepezil.
   Google Scholar
• FRIEDHOFF LT, ROGERS SL: Correlation between the clinical efficacy of donepezil HC1 (E2020) and red blood cell (RBC) acetylcholinesterase (AChE) inhibition in patients with Alzheimer's disease (AD). Clin. Pharmacol. Ther. (1997) 61:177.
   Google Scholar
• ROGERS SL, DOODY R, MOHS R, FRIEDHOFF LT: E2020produces both clinical global and cognitive test im-provement in patients with mild to moderately severe Alzheimer's disease: results of a 30 week Phase III trial. Neurology (1996) 46 (Suppl .):A217.
   Google Scholar